Biology of Fibrosis in IBD RFP
Overview: Half of all Crohn's disease (CD) patients will develop disease complications, one which is development of fibrotic strictures (fibrostenosis), leading to GI tract obstruction and severe clinical consequences. Fibrostenosis is also a serious problem for ulcerative colitis (UC) with approximately 8% incidence over the lifetime. Currently there is no clinical solution for preventing or treating fibrostenosis in patients with inflammatory bowel disease (IBD), except for surgical intervention. Therefore, there is a great unmet need to understand fibrotic complications in IBD and how to prevent and treat them.
Scope: The Crohn's & Colitis Foundation seeks to fund studies focused on investigating the biological mechanisms leading to, and protecting from, fibrosis in IBD. These studies should be built upon clinical observations and/or published evidence in human IBD. Particular interest will be on proposals that address one or more of the following areas:
- Pathophysiology of fibrosis based on documented patterns of gene expression
- Cell biological mechanisms of fibrosis – role of different cell types
- Biology of strictureplasty
Eligibility: Applications from teams with complementary expertise in IBD and fibrosis, with one lead Principal Investigator (PI, Professor, Head of Research, Associate Professor) and at least one junior Co-PI (Instructor or Assistant Professor). A multidisciplinary approach is preferred, for example, studies including in vitro models (e.g. human intestinal organoids), analysis of human biopsies, animal models of fibrosis, biophysical studies, and imaging approaches. US and international researchers are encouraged to apply.
Funding Terms: $900,000 for three years ($300,000/year, contingent on reaching annual milestones)
Application Deadline: September 7, 2018
How to apply
Applications are not currently being accepted for this RFP.
Questions? Contact Dr. Nataly Shtraizent at NShtraizent@crohnscolitisfoundation.org